PUBLICATIONS

Representative Publications

Recent publications from our lab in cancer genomics, targeted therapy, epigenetics, and antiviral research.

2025
ARTICLE

Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens

Wei Jiang#, Ailing Yang#, Jingchuan Ma#, Dawei Lv#, Mingxian Liu, Chao Wang, Shuo Chen, Huiling Fang, Yankai Chu, Zhengjin He, Wenrui Li, Yucheng Liu, Yun Zhao, Zhaocai Zhou, Gang Long, Hai Jiang*

Antiviral Research 2025
DOI: 10.1016/j.antiviral.2025.106309
ARTICLE

STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency

Zhengjin He#, Shishuang Chen#, Jinlong Suo#, Kai Xia#, Mingxian Liu, Jingchuan Ma, Yankai Chu, Chao Wang, Yueru Xie, Wei Jiang, Hui Du, Shiyang Chen, Zhilei Zhou, Man Li, Qing Wei, Yun Zhao, Jianfeng Chen, Lin Li, Yi Zeng, Weiguo Zou, Moubin Lin*, Hai Jiang*

Cell Chemical Biology 2025
DOI: 10.1016/j.chembiol.2025.10.006
ARTICLE

A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2

Yankai Chu#, Shishuang Chen#, Man Yang#, Yu Chen#, Huiling Fang#, Pei Huang, Yueru Xie, Chen Sun, Yuzhe Chen, Bo Zhang, Lin Li, Hong Mu, Dan Song, Wen Cheng, Chao Wang, Wei Jiang, Xin Xu, Zhengjin He, Shuang Chen, Mingxian Liu, Jingchuan Ma, Ming Yang, Jin Cao, Jing Shen, Lei Zhang, Yu Bai, Ziqi Liu, Jian Chen, Shang Dai, Yi Zeng, Yun Zhao, Hu Zhou, Ceshi Chen, Hongwei Ru, Li Tan, Xin Chi, Fang Wang, Daming Gao, Moubin Lin, Xianming Deng*, Hai Jiang*

Nature Biotechnology 2025
DOI: 10.1038/s41587-025-02793-8
ARTICLE

Catalytic-independent functions of Integrator/INTAC confer sensitivity to BET inhibition

Peng Fan#, Xueyi Shang#, Aihua Song#, Shuo Chen#, Ruiyuan Mao#, Jingchuan Ma#, Jie Chen, Zicheng Wang, Hai Zheng, Bing Tao, Li Hong, Jing Liu, Wei Xu, Wei Jiang, Hui Shen, Qi Zhang, Hui Yang, Xiangmei Meng, Fei Lan, Jie Cheng, Chen Xu, Peng Zhang*, Hai Jiang*, Fei Chen*

Nature Chemical Biology 21(6):959-970 2025
DOI: 10.1038/s41589-024-01820-0
2024
REVIEW

Small-molecule drug screening and applications targeting RNA

陈硕#, 杨曼#, 姜海*

Chemistry of Life 44(9): 1-9 2024
DOI: 10.13488/j.smhx.20240454
2023
ARTICLE

DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines

Yun Zhao#, Wei Jiang#, Haiping Gao#, Guoping Pan, Yong Wu, Yubo Wang, Mengya Sheng, Jiajia Xie, Wei Wu, Zhiliang Ji, Yunfei Du, Leilei Zhang, Xiaodong Wang, Colum P. Walsh, Hai Jiang*, Guoliang Xu*, Daizhan Zhou*

Protein & Cell 14(7):532-537 2023
DOI: 10.1093/procel/pwac028
2020
ARTICLE

Defining relative mutational difficulty to understand cancer formation

Lin Shan#, Jiao Yu#, Zhengjin He, Shishuang Chen, Mingxian Liu, Hongyu Ding, Liang Xu, Jie Zhao, Ailing Yang, Hai Jiang*

Cell Discovery 6:48 2020
DOI: 10.1038/s41421-020-0177-8
ARTICLE

SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signaling

Liang Xu, Peixue Li, Xue Hao, Yi Lu, Mingxian Liu, Wenqian Song, Lin Shan, Jiao Yu, Hongyu Ding, Shishuang Chen, Ailing Yang, Yi Arial Zeng, Lei Zhang, Hai Jiang*

Protein & Cell 2020
DOI: 10.1007/s13238-020-00742-6
2019
REVIEW

The expanding vulnerabilities of being UTXless

Hai Jiang*

Signal Transduction and Targeted Therapy 4:12 2019
DOI: 10.1038/s41392-019-0047-6
ARTICLE

Systematic analysis of drug vulnerabilities conferred by tumor suppressor loss

Hongyu Ding, Jie Zhao, Ying Zhang, Jiao Yu, Mingxian Liu, Xue Li, Liang Xu, Moubin Lin, Chao Liu, Zhengjin He, Shishuang Chen, Hai Jiang*

Cell Reports 27:3331-3344 2019
DOI: 10.1016/j.celrep.2019.05.079
2018
ARTICLE

UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma

Xue Li, Ying Zhang, Liting Zheng, Mingxian Liu, Charlie D. Chen, Hai Jiang*

Nature Communications 9(1):2720 2018
DOI: 10.1038/s41467-018-05084-w
2015
ARTICLE

A DNA/HDAC dual-targeting drug with significantly enhanced anticancer potency

Chao Liu, Hongyu Ding, Xue Li, Christian P. Pallasch, Li Hong, Delong Guo, Yi Chen, Dongfang Wang, Wei Wang, Yanli Wang*, Michael T. Hemann*, Hai Jiang*

EMBO Molecular Medicine 7(4):438-449 2015
DOI: 10.15252/emmm.201404580
ARTICLE

A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk

Ning Wang, Hongyu Ding, Hongxia Liu, Xue Li, Lixiang Wei, Jiao Yu, Mingxian Liu, Ming Ying, Weimin Gao, Hai Jiang*, Yan Wang*

Oncogene 34(40):5198-5205 2015
DOI: 10.1038/onc.2014.443